$CLVS JUST OUT!!! PARPi's may potentiate the effectiveness of Tocilizumab, Anakinra, Sarilumab, Adalimumab, Canakinumab or Siltuximab therapy. In summary, the evidence suggests that PARPi therapy would benefit COVID-19 patients and trials of these drugs should be undertaken. "Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?" pubmed.ncbi.nlm.nih.gov/324...
  • 9
9 Likes